Patient-Driven Research Goes Mainstream: How One Baby’s Trial Is Transforming Medicine

The first successful use of a personalized CRISPR-based gene editing therapy to treat an infant with a rare, life-threatening genetic disease has been reported, marking a significant milestone in precision medicine.

The infant, identified as KJ, was diagnosed shortly after birth with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, a rare metabolic disorder that disrupts the body’s ability to process ammonia and can lead to dangerous buildup in the blood. Without treatment, the condition is often fatal in early infancy.

Developed by a research team at Children’s Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania, the therapy was designed to correct a specific mutation in one copy of the CPS1 gene in the infant’s liver cells. Using a base editing approach — a refined form of CRISPR technology — the treatment aimed to make precise changes to DNA without cutting the double helix, reducing the risk of unintended genetic alterations.

The therapy was delivered via lipid nanoparticles carrying messenger RNA that encoded the gene-editing tools. After six months of development from diagnosis to treatment — an unusually rapid timeline for such a personalized intervention — the infant received the first dose in February 2025, between six and seven months of age.

According to the research team, the treatment was administered safely, and the infant has since shown positive clinical responses, including improved metabolic stability and growth. The child is now growing well and thriving, having transitioned from a highly restrictive diet to a more normal feeding regimen.

The approach represents a potential pathway for treating hundreds of other rare genetic diseases for which no therapies currently exist. By using a modular platform that can be rapidly adapted to target different mutations, the method could allow for customized therapies to be designed and delivered quickly, particularly when early intervention is critical.

As noted by Joni L. Rutter, Ph.D., director of the National Center for Advancing Translational Sciences at the National Institutes of Health, which supported the research, “As a platform, gene editing — built on reusable components and rapid customization — promises a new era of precision medicine for hundreds of rare diseases, bringing life-changing therapies to patients when timing matters most: Early, fast, and tailored to the individual.”

The case was detailed in a study published in The New England Journal of Medicine and presented at the American Society of Gene & Cell Therapy Annual Meeting in New Orleans. It is also the subject of a recent commentary in Nature Medicine titled “The patient is now in the room,” which highlights how patient-driven research initiatives are accelerating the translation of experimental therapies into clinical use.

While the results are promising, researchers emphasize that long-term monitoring is needed to assess the durability of the treatment effects and to watch for any potential late-onset complications. The therapy remains investigational, and further studies will be required to determine its broader applicability and safety across different patients and genetic conditions.

This development underscores the growing potential of gene editing technologies to address unmet medical needs in rare diseases, particularly when guided by rapid development platforms and close collaboration between academic medical centers, regulators, and families.